Twinbeech Capital LP Sells 105,944 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Twinbeech Capital LP lessened its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,558 shares of the biopharmaceutical company's stock after selling 105,944 shares during the quarter. Twinbeech Capital LP owned 0.05% of Celldex Therapeutics worth $873,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Invesco Ltd. boosted its holdings in shares of Celldex Therapeutics by 2.1% in the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after purchasing an additional 871 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after purchasing an additional 1,400 shares in the last quarter. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 1,647 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Celldex Therapeutics by 6.1% in the 4th quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company's stock valued at $1,001,000 after purchasing an additional 2,288 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, May 6th. UBS Group cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Morgan Stanley cut their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Stock Down 2.3%

CLDX traded down $0.47 during midday trading on Tuesday, hitting $19.88. 146,337 shares of the company were exchanged, compared to its average volume of 894,559. The firm has a market capitalization of $1.32 billion, a P/E ratio of -7.76 and a beta of 1.39. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The firm's 50 day moving average price is $18.92 and its 200-day moving average price is $22.31.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. On average, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.